The trajectory of companies tied to iconic drugs like Viagra presents a challenging investment scenario . While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the expiry in key regions has introduced considerable uncertainty . Investors are now assessing the consequences of rival medicati